Table 2 Involved mechanisms or effects of modulators of SIRT1 in asthma
Modulators | Models or specimens | Involved mechanisms or effects |
|---|---|---|
Activators | Â | Â |
SRT1720 [38] | OVA-induced asthma mouse model | Decrease total and eosinophil cell counts and IL-5 and IL-13 levels in the BAL fluid, alleviate inflammatory cell lung infiltrates histologically, suppress cell proliferation, decrease IL-6 and TNF-α production in splenocytes |
Resveratrol [38] | OVA-induced asthma mouse model | Suppress cell proliferation, decrease IL-6 and TNF-α production in splenocytes |
Resveratrol [40] | OVA-induced asthma mouse model | Alleviate OVA-induced airway inflammation and airway remodeling via PTEN pathway |
Gentiopicroside [41] | OVA-induced asthma mouse model | Alleviate airway inflammation through regulating SIRT1/NF-κB p65 signaling pathway |
Inhibitors | Â | Â |
Sirtinol [33] | PBMCs from healthy subjects, CD4 + CD45RA + T cells from human cord blood, and HUT78 T lymphocytes | Increase the expression of Th2-associated cytokines, and increase acetylation of GATA-3 protein |
Salermide [39] | human airway epithelial cell line 16HBE, and OVA-induced asthma mouse model | Increased IL-6 mRNA and protein levels via activation of Akt |
Sirtinol [54] | OVA-induced asthma mouse model | Attenuate airway inflammation and hyperresponsiveness through the modulation of vascular endothelial growth factor expression mediated by HIF-1α |
Cambinol [55] | OVA-induced asthma mouse model | Alleviate airway inflammation and hyperresponsiveness, decrease Th2 cytokine production and T cell proliferation in DCs through the derepression of PPAR-γ |
Sirtinol [55] | OVA-induced asthma mouse model | Alleviate airway inflammation and hyperresponsiveness, decrease Th2 cytokine production and T cell proliferation in DCs through the derepression of PPAR-γ |
EX-527 [56] | OVA-induced asthma mouse model | Reduce airway inflammation through the mTOR-mediated autophagy pathway |